Exhibit 99.1 Net income of $4.0 million, or$0.65 and $0.21 net income per share basic and diluted, respectively Adjusted EBITDA1 of$3.9 million Total net revenue of $18.5 million up 32% year-over-year Company to host conference call and webcast today, May 14, 2025, at 4:30 p.m. Eastern time DENVER, CO / May 14, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced operational and financial results for th ...